Figure 5. Nanoparticles containing MRX-2843 and vincristine at an additive ratio mediate superior antileukemia activity in a murine ETP-ALL xenograft model.

a,b) NRG mice were inoculated with a luciferase-expressing ETP-ALL cell line (LOUCY-luc; 2 million cells). Mice were randomized to groups with equal starting disease burden (n=7–8) and treatment with synergistic (Syn) or additive (Add) liposomal formulations of MRX-2843 and vincristine or vehicle nanoparticles without drug (Veh) was initiated 20 days later. Arrows indicate treatment administration. c) Disease burden was determined at intervals by bioluminescence imaging. Data are reported as mean ± SEM. Differences were determined by two-way ANOVA. d) Differences in median survival (MS) were calculated by the log-rank method. e,f) NRG mice were inoculated intravenously with 3 million LOUCY-luc cells, then randomized to groups (n=9–10) and treatment with the indicated liposomal formulations of MRX-2843 and vincristine or Veh was initiated 20 days later. f) Differences in median survival were calculated by the log-rank method.